eli lilly retatrutide trials ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Drug retatrutide helps people lower

The telogen hairs that entered the resting phase two to three months ago begin falling out as new hairs push through underneath

Accessed May 21, 2025

The glucagon receptor agonism, whilst counterintuitive given glucagon's role in raising blood glucose, is thought to increase energy expenditure and promote hepatic fat oxidation whilst reducing lipogenesis effects that may offer potential benefits in metabolic dysfunction-associated steatotic liver disease (MASLD)

And TRANSCEND-T2D-1, part of a separate three-trial diabetes-specific program, confirmed -2.0% HbA1c reduction and 16.8% weight loss in 537 type 2 diabetes patients (topline March 2026, published in The Lancet, June 2026)

Keep moving

Therefore, it is important to assess the impact of the new large-volume syringe on the fill-and-finish landscape